hotspot -WSS

hotspot

author：focus 2025-09-06 04:36:33 - browse：8

In a surprise move, the Food and Drug Administration has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved, even as many outsiders expected the medicine to receive regulatory clearance this month.

The drug, donanemab, succeeded in its Phase 3 trial, resulting in a 35% slowing of Alzheimer’s disease progression versus placebo. But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design” of the study.

A date for the meeting has not been set yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Lindsay Lohan welcomes 1st child with husband Bader Shammas

hotspot

WSS

Update the Apgar Score to remove skin color

States increasingly look to regulate hospital facility fees

High breast density mammograms need follow

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

To bolster infectious disease surveillance, genomics powerhouses team up

Pumping milk in bathrooms at health conferences is common

leisure time

hotspot

focus

As demand for Covid shots wanes, Moderna seeks its next success

CVS is on a mission to consolidate health care. Will it work?

Activists slam private health insurers over coverage restrictions

Couple fighting to bring baby home from Mexico are finally reunited

Heart attack and stroke risk calculators need revising

Researchers separate signal from noise in heart wearable data

How to save PrEP access — and even expand it

New warning issued for rebooking air travel after delays, cancellations

Wildfire smoke exposes gaps in outdoor worker protections

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

explore

Microsoft launches AI tool for clinical documentation through Epic

Maisha Meds is a PBM, but don't call it that

TikTok cracks down on users posting about weight loss drugs

CVS is on a mission to consolidate health care. Will it work?

Resistance to cancer drugs: A new genetic explanation

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Wikipedia

focus

hotspot

focus